Drug safety in Crohn's disease therapy

Détails

ID Serval
serval:BIB_1E77D476CD2D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Drug safety in Crohn's disease therapy
Périodique
Digestion
Auteur(s)
Juillerat Pascal, Pittet Valérie, Felley Christian, Mottet Christian, Froehlich Florian, Vader John-Paul, Gonvers Jean-Jacques, Michetti Pierre
ISSN
0012-2823
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
76
Numéro
2
Pages
161-168
Langue
anglais
Résumé
The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy. Above all the most frequent adverse events and the data on the long-term safety of the therapeutic arsenal available to the physician will be taken into consideration. The drugs described in this article include 5-ASA compounds, antibiotics (metronidazole, ciprofloxacin and rifaximin), corticosteroids (budesonide, prednisone and equivalents), thiopurines (azathioprine and 6-mercaptopurine), methotrexate, anti-tumor necrosis factor inhibitors (infliximab, adalimumab, certolizumab), natalizumab, anticalcineurin inhibitors (cyclosporine, tacrolimus) and mycophenolate mofetil. [Ed.]
Mots-clé
Adrenal Cortex Hormones, Adrenal Cortex Hormones/standards, Adrenal Cortex Hormones/therapeutic use, Anti-Bacterial Agents, Anti-Bacterial Agents/standards, Anti-Bacterial Agents/therapeutic use, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal/standards, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Crohn Disease, Crohn Disease/drug therapy, Dose-Response Relationship, Drug, Humans, Immunosuppressive Agents, Immunosuppressive Agents/standards, Immunosuppressive Agents/therapeutic use, Risk Factors, Safety
Pubmed
Web of science
Création de la notice
03/03/2008 11:52
Dernière modification de la notice
03/03/2018 14:36
Données d'usage